Kamada Ltd. (NASDAQ: KMDA) Stock Competitors & Peer Comparison
See KMDA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for KMDA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KMDA | $8.13 | +0.37% | 469.1M | 21.39 | $0.38 | +5.22% |
| TAK | $20.84 | -0.43% | 65.3B | 14.99 | $1.39 | +3.38% |
| TEVA | $43.24 | +1.98% | 50.4B | 14.75 | $2.93 | N/A |
| HLN | $9.10 | +0.44% | 40.3B | 18.59 | $0.49 | +2.19% |
| ZTS | $82.57 | +0.13% | 33.5B | 12.55 | $6.58 | +2.56% |
| VTRS | $21.06 | +1.01% | 24.1B | 8.36 | $2.52 | +2.31% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $26.48 | -1.05% | 13.2B | 24.98 | $1.06 | N/A |
| RDY | $14.84 | -0.13% | 12.4B | 31.57 | $0.47 | +0.56% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
KMDA vs TAK Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TAK has a market cap of 65.3B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TAK trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TAK's P/E ratio is 14.99. In terms of profitability, KMDA's ROE is +0.09%, compared to TAK's ROE of +0.05%. Regarding short-term risk, KMDA is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
KMDA vs TEVA Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TEVA has a market cap of 50.4B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TEVA trades at $43.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TEVA's P/E ratio is 14.75. In terms of profitability, KMDA's ROE is +0.09%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, KMDA is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TEVA's competition here
Haleon plc (NYSE: HLN)
KMDA vs HLN Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, HLN has a market cap of 40.3B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while HLN trades at $9.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas HLN's P/E ratio is 18.59. In terms of profitability, KMDA's ROE is +0.09%, compared to HLN's ROE of +0.10%. Regarding short-term risk, KMDA is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
KMDA vs ZTS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ZTS has a market cap of 33.5B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ZTS trades at $82.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ZTS's P/E ratio is 12.55. In terms of profitability, KMDA's ROE is +0.09%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, KMDA is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
KMDA vs VTRS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, VTRS has a market cap of 24.1B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while VTRS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas VTRS's P/E ratio is 8.36. In terms of profitability, KMDA's ROE is +0.09%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, KMDA is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
KMDA vs ITCI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ITCI's P/E ratio is -180.64. In terms of profitability, KMDA's ROE is +0.09%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, KMDA is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
KMDA vs ELAN Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ELAN has a market cap of 13.2B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ELAN trades at $26.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ELAN's P/E ratio is 24.98. In terms of profitability, KMDA's ROE is +0.09%, compared to ELAN's ROE of -0.02%. Regarding short-term risk, KMDA is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
KMDA vs RDY Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while RDY trades at $14.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas RDY's P/E ratio is 31.57. In terms of profitability, KMDA's ROE is +0.09%, compared to RDY's ROE of +0.07%. Regarding short-term risk, KMDA is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check RDY's competition here
Catalent, Inc. (NYSE: CTLT)
KMDA vs CTLT Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CTLT's P/E ratio is -27.84. In terms of profitability, KMDA's ROE is +0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, KMDA is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check CTLT's competition here
Alkermes plc (NASDAQ: ALKS)
KMDA vs ALKS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ALKS trades at $47.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ALKS's P/E ratio is 50.41. In terms of profitability, KMDA's ROE is +0.09%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, KMDA is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ALKS's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
KMDA vs AMRX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, AMRX has a market cap of 7.6B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while AMRX trades at $21.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas AMRX's P/E ratio is 24.12. In terms of profitability, KMDA's ROE is +0.09%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, KMDA is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check AMRX's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
KMDA vs LNTH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while LNTH trades at $101.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas LNTH's P/E ratio is 17.08. In terms of profitability, KMDA's ROE is +0.09%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, KMDA is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check LNTH's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
KMDA vs INDV Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while INDV trades at $36.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas INDV's P/E ratio is 9.94. In terms of profitability, KMDA's ROE is +0.09%, compared to INDV's ROE of -3.53%. Regarding short-term risk, KMDA is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check INDV's competition here
Bausch Health Companies Inc. (NYSE: BHC)
KMDA vs BHC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while BHC trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas BHC's P/E ratio is 2.13. In terms of profitability, KMDA's ROE is +0.09%, compared to BHC's ROE of +0.59%. Regarding short-term risk, KMDA is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check BHC's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
KMDA vs RGC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas RGC's P/E ratio is -541.00. In terms of profitability, KMDA's ROE is +0.09%, compared to RGC's ROE of -1.61%. Regarding short-term risk, KMDA is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check RGC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
KMDA vs HCM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, HCM has a market cap of 2.6B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while HCM trades at $15.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas HCM's P/E ratio is 145.84. In terms of profitability, KMDA's ROE is +0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, KMDA is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check HCM's competition here
Perrigo Company plc (NYSE: PRGO)
KMDA vs PRGO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while PRGO trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas PRGO's P/E ratio is 6.62. In terms of profitability, KMDA's ROE is +0.09%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, KMDA is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
KMDA vs DCPH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas DCPH's P/E ratio is -11.58. In terms of profitability, KMDA's ROE is +0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, KMDA is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
KMDA vs AVDL Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, KMDA's ROE is +0.09%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, KMDA is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check AVDL's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
KMDA vs ETON Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ETON has a market cap of 2B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ETON trades at $68.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ETON's P/E ratio is 180.00. In terms of profitability, KMDA's ROE is +0.09%, compared to ETON's ROE of +1.05%. Regarding short-term risk, KMDA is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ETON's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
KMDA vs TRLV Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TRLV has a market cap of 1.9B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TRLV trades at $11.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TRLV's P/E ratio is -4.57. In terms of profitability, KMDA's ROE is +0.09%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, KMDA is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
KMDA vs EMBCV Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas EMBCV's P/E ratio is N/A. In terms of profitability, KMDA's ROE is +0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, KMDA is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
KMDA vs DVAX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas DVAX's P/E ratio is -41.89. In terms of profitability, KMDA's ROE is +0.09%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, KMDA is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
KMDA vs ALVO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ALVO trades at $4.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ALVO's P/E ratio is -8.34. In terms of profitability, KMDA's ROE is +0.09%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, KMDA is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ALVO's competition here
Supernus, Inc. (NASDAQ: SUPN)
KMDA vs SUPN Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SUPN has a market cap of 1.7B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SUPN trades at $29.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SUPN's P/E ratio is -38.89. In terms of profitability, KMDA's ROE is +0.09%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, KMDA is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check SUPN's competition here
Alvotech (NASDAQ: ALVOW)
KMDA vs ALVOW Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ALVOW has a market cap of 1.7B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ALVOW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ALVOW's P/E ratio is 26.59. In terms of profitability, KMDA's ROE is +0.09%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, KMDA is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check ALVOW's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
KMDA vs ANIP Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ANIP trades at $71.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ANIP's P/E ratio is 8.65. In terms of profitability, KMDA's ROE is +0.09%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, KMDA is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
KMDA vs TARO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TARO's P/E ratio is 30.05. In terms of profitability, KMDA's ROE is +0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, KMDA is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check TARO's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
KMDA vs PCRX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while PCRX trades at $36.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas PCRX's P/E ratio is 14.02. In terms of profitability, KMDA's ROE is +0.09%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, KMDA is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check PCRX's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
KMDA vs PAHC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while PAHC trades at $35.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas PAHC's P/E ratio is 12.00. In terms of profitability, KMDA's ROE is +0.09%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, KMDA is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check PAHC's competition here
Cronos Group Inc. (NASDAQ: CRON)
KMDA vs CRON Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CRON trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CRON's P/E ratio is 17.67. In terms of profitability, KMDA's ROE is +0.09%, compared to CRON's ROE of +0.05%. Regarding short-term risk, KMDA is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
KMDA vs AMPH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while AMPH trades at $28.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas AMPH's P/E ratio is 9.76. In terms of profitability, KMDA's ROE is +0.09%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, KMDA is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
KMDA vs HROW Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, HROW has a market cap of 1.1B. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while HROW trades at $29.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas HROW's P/E ratio is -29.67. In terms of profitability, KMDA's ROE is +0.09%, compared to HROW's ROE of -0.91%. Regarding short-term risk, KMDA is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
KMDA vs PETQ Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas PETQ's P/E ratio is 83.73. In terms of profitability, KMDA's ROE is +0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, KMDA is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check PETQ's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
KMDA vs IRWD Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, IRWD has a market cap of 806.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while IRWD trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas IRWD's P/E ratio is 6.24. In terms of profitability, KMDA's ROE is +0.09%, compared to IRWD's ROE of -0.81%. Regarding short-term risk, KMDA is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check IRWD's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
KMDA vs COLL Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, COLL has a market cap of 771M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while COLL trades at $24.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas COLL's P/E ratio is 3.11. In terms of profitability, KMDA's ROE is +0.09%, compared to COLL's ROE of +0.12%. Regarding short-term risk, KMDA is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
KMDA vs EVO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while EVO trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas EVO's P/E ratio is -2.39. In terms of profitability, KMDA's ROE is +0.09%, compared to EVO's ROE of -0.26%. Regarding short-term risk, KMDA is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
KMDA vs BDSI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas BDSI's P/E ratio is 6.82. In terms of profitability, KMDA's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, KMDA is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check BDSI's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
KMDA vs TKNO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TKNO has a market cap of 541M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TKNO trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TKNO's P/E ratio is -27.81. In terms of profitability, KMDA's ROE is +0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, KMDA is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TKNO's competition here
Evolus, Inc. (NASDAQ: EOLS)
KMDA vs EOLS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, EOLS has a market cap of 491.1M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while EOLS trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas EOLS's P/E ratio is -23.50. In terms of profitability, KMDA's ROE is +0.09%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, KMDA is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
KMDA vs AQST Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, AQST has a market cap of 450M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while AQST trades at $3.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas AQST's P/E ratio is -5.51. In terms of profitability, KMDA's ROE is +0.09%, compared to AQST's ROE of +2.55%. Regarding short-term risk, KMDA is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check AQST's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
KMDA vs ACB Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ACB has a market cap of 332M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ACB trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ACB's P/E ratio is -3.65. In terms of profitability, KMDA's ROE is +0.09%, compared to ACB's ROE of -0.15%. Regarding short-term risk, KMDA is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check ACB's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
KMDA vs EBS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, EBS has a market cap of 310.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while EBS trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas EBS's P/E ratio is 4.19. In terms of profitability, KMDA's ROE is +0.09%, compared to EBS's ROE of -0.61%. Regarding short-term risk, KMDA is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
KMDA vs ALIM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ALIM's P/E ratio is 5.28. In terms of profitability, KMDA's ROE is +0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, KMDA is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check ALIM's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
KMDA vs TLRY Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TLRY has a market cap of 291.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TLRY trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TLRY's P/E ratio is -1.86. In terms of profitability, KMDA's ROE is +0.09%, compared to TLRY's ROE of -0.10%. Regarding short-term risk, KMDA is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TLRY's competition here
Landec Corporation (NASDAQ: LNDC)
KMDA vs LNDC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas LNDC's P/E ratio is -4.04. In terms of profitability, KMDA's ROE is +0.09%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, KMDA is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check LNDC's competition here
Canopy Growth Corporation (NASDAQ: CGC)
KMDA vs CGC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CGC has a market cap of 256.1M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CGC trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CGC's P/E ratio is -1.35. In terms of profitability, KMDA's ROE is +0.09%, compared to CGC's ROE of -0.37%. Regarding short-term risk, KMDA is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check CGC's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
KMDA vs LFCR Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, LFCR has a market cap of 242.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while LFCR trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas LFCR's P/E ratio is -5.04. In terms of profitability, KMDA's ROE is +0.09%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, KMDA is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
KMDA vs TYHT Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TYHT's P/E ratio is -1.61. In terms of profitability, KMDA's ROE is +0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, KMDA is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
KMDA vs SIGA Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SIGA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SIGA's P/E ratio is 11.63. In terms of profitability, KMDA's ROE is +0.09%, compared to SIGA's ROE of -0.20%. Regarding short-term risk, KMDA is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
KMDA vs REPH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas REPH's P/E ratio is -8.04. In terms of profitability, KMDA's ROE is +0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, KMDA is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check REPH's competition here
Glass House Brands Inc (NYSE: GLAS)
KMDA vs GLAS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, GLAS has a market cap of 166.8M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while GLAS trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas GLAS's P/E ratio is -3.39. In terms of profitability, KMDA's ROE is +0.09%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, KMDA is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check GLAS's competition here
Theratechnologies Inc. (NASDAQ: THTX)
KMDA vs THTX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas THTX's P/E ratio is -28.83. In terms of profitability, KMDA's ROE is +0.09%, compared to THTX's ROE of +0.36%. Regarding short-term risk, KMDA is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
KMDA vs ASRT Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ASRT's P/E ratio is -7.10. In terms of profitability, KMDA's ROE is +0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, KMDA is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check ASRT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
KMDA vs ORGO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ORGO has a market cap of 136.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ORGO trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ORGO's P/E ratio is 35.00. In terms of profitability, KMDA's ROE is +0.09%, compared to ORGO's ROE of -0.47%. Regarding short-term risk, KMDA is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ORGO's competition here
Journey Medical Corporation (NASDAQ: DERM)
KMDA vs DERM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, DERM has a market cap of 125.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while DERM trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas DERM's P/E ratio is -20.18. In terms of profitability, KMDA's ROE is +0.09%, compared to DERM's ROE of -0.20%. Regarding short-term risk, KMDA is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
KMDA vs CRDL Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CRDL has a market cap of 121.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CRDL trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CRDL's P/E ratio is -4.02. In terms of profitability, KMDA's ROE is +0.09%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, KMDA is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
KMDA vs OGI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, OGI has a market cap of 120.4M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while OGI trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas OGI's P/E ratio is 1.92. In terms of profitability, KMDA's ROE is +0.09%, compared to OGI's ROE of +0.21%. Regarding short-term risk, KMDA is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check OGI's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
KMDA vs SCTL Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SCTL's P/E ratio is -7.86. In terms of profitability, KMDA's ROE is +0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, KMDA is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
KMDA vs BGM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, BGM has a market cap of 110.4M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while BGM trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas BGM's P/E ratio is -1.81. In terms of profitability, KMDA's ROE is +0.09%, compared to BGM's ROE of -0.05%. Regarding short-term risk, KMDA is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
KMDA vs PROC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas PROC's P/E ratio is 1.53. In terms of profitability, KMDA's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, KMDA is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
KMDA vs OPTN Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas OPTN's P/E ratio is -4.42. In terms of profitability, KMDA's ROE is +0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, KMDA is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
KMDA vs ZOM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ZOM's P/E ratio is -1.62. In terms of profitability, KMDA's ROE is +0.09%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, KMDA is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ZOM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
KMDA vs CPIX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CPIX has a market cap of 91.7M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CPIX trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CPIX's P/E ratio is -15.30. In terms of profitability, KMDA's ROE is +0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, KMDA is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check CPIX's competition here
Upexi, Inc. (NASDAQ: GRVI)
KMDA vs GRVI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas GRVI's P/E ratio is 26.05. In terms of profitability, KMDA's ROE is +0.09%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, KMDA is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
KMDA vs ZYBT Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ZYBT has a market cap of 71.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ZYBT trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ZYBT's P/E ratio is -7.55. In terms of profitability, KMDA's ROE is +0.09%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, KMDA is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
KMDA vs ZYNE Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, KMDA's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, KMDA is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
KMDA vs SSIC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SSIC's P/E ratio is 11.93. In terms of profitability, KMDA's ROE is +0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, KMDA is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
KMDA vs VLNS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas VLNS's P/E ratio is -1.03. In terms of profitability, KMDA's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, KMDA is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
KMDA vs DRRX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas DRRX's P/E ratio is -4.44. In terms of profitability, KMDA's ROE is +0.09%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, KMDA is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
KMDA vs TLPH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TLPH has a market cap of 54.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TLPH trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TLPH's P/E ratio is -3.89. In terms of profitability, KMDA's ROE is +0.09%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, KMDA is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
KMDA vs INCR Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, INCR has a market cap of 51.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while INCR trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas INCR's P/E ratio is -4.16. In terms of profitability, KMDA's ROE is +0.09%, compared to INCR's ROE of -0.09%. Regarding short-term risk, KMDA is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
KMDA vs JUPW Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas JUPW's P/E ratio is -2.41. In terms of profitability, KMDA's ROE is +0.09%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, KMDA is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
KMDA vs QLI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas QLI's P/E ratio is -4.92. In terms of profitability, KMDA's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, KMDA is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
KMDA vs HEXO Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas HEXO's P/E ratio is -0.26. In terms of profitability, KMDA's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, KMDA is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
KMDA vs RMTI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while RMTI trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas RMTI's P/E ratio is -5.28. In terms of profitability, KMDA's ROE is +0.09%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, KMDA is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check RMTI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
KMDA vs SHPH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SHPH has a market cap of 25M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SHPH trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SHPH's P/E ratio is -0.24. In terms of profitability, KMDA's ROE is +0.09%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, KMDA is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
KMDA vs CYTH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CYTH's P/E ratio is -0.80. In terms of profitability, KMDA's ROE is +0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, KMDA is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check CYTH's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
KMDA vs CPHI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CPHI has a market cap of 22.7M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CPHI trades at $0.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CPHI's P/E ratio is -1.23. In terms of profitability, KMDA's ROE is +0.09%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, KMDA is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check CPHI's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
KMDA vs TXMD Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, TXMD has a market cap of 20.8M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while TXMD trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas TXMD's P/E ratio is 91.70. In terms of profitability, KMDA's ROE is +0.09%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, KMDA is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
KMDA vs AYTU Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, AYTU has a market cap of 20M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while AYTU trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas AYTU's P/E ratio is -1.56. In terms of profitability, KMDA's ROE is +0.09%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, KMDA is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
KMDA vs EVOK Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas EVOK's P/E ratio is -7.97. In terms of profitability, KMDA's ROE is +0.09%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, KMDA is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
KMDA vs ACRX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ACRX's P/E ratio is -0.31. In terms of profitability, KMDA's ROE is +0.09%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, KMDA is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ACRX's competition here
Optimi Health Corp. (NASDAQ: OPTH)
KMDA vs OPTH Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, OPTH has a market cap of 13.7M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while OPTH trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas OPTH's P/E ratio is -1.54. In terms of profitability, KMDA's ROE is +0.09%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, KMDA is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check OPTH's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
KMDA vs AGRX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas AGRX's P/E ratio is -0.89. In terms of profitability, KMDA's ROE is +0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, KMDA is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check AGRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
KMDA vs CABR Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, CABR has a market cap of 8.6M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while CABR trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas CABR's P/E ratio is -1.21. In terms of profitability, KMDA's ROE is +0.09%, compared to CABR's ROE of -3.86%. Regarding short-term risk, KMDA is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check CABR's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
KMDA vs INM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, INM has a market cap of 8.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while INM trades at $15.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas INM's P/E ratio is -5.07. In terms of profitability, KMDA's ROE is +0.09%, compared to INM's ROE of -3.04%. Regarding short-term risk, KMDA is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check INM's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
KMDA vs NLTX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas NLTX's P/E ratio is -0.28. In terms of profitability, KMDA's ROE is +0.09%, compared to NLTX's ROE of -0.44%. Regarding short-term risk, KMDA is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
KMDA vs LCI Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas LCI's P/E ratio is -0.04. In terms of profitability, KMDA's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, KMDA is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
KMDA vs ADMP Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ADMP's P/E ratio is -0.08. In terms of profitability, KMDA's ROE is +0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, KMDA is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
KMDA vs SNOA Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SNOA has a market cap of 5.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SNOA trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SNOA's P/E ratio is -1.12. In terms of profitability, KMDA's ROE is +0.09%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, KMDA is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check SNOA's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
KMDA vs SBFM Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SBFM trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SBFM's P/E ratio is -0.45. In terms of profitability, KMDA's ROE is +0.09%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, KMDA is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check SBFM's competition here
Mallinckrodt plc (AMEX: MNK)
KMDA vs MNK Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas MNK's P/E ratio is -0.44. In terms of profitability, KMDA's ROE is +0.09%, compared to MNK's ROE of -0.33%. Regarding short-term risk, KMDA is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check MNK's competition here
cbdMD, Inc. (AMEX: YCBD)
KMDA vs YCBD Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, YCBD has a market cap of 4.4M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while YCBD trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas YCBD's P/E ratio is -0.97. In terms of profitability, KMDA's ROE is +0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, KMDA is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check YCBD's competition here
Flora Growth Corp. (NASDAQ: FLGC)
KMDA vs FLGC Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas FLGC's P/E ratio is -0.19. In terms of profitability, KMDA's ROE is +0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, KMDA is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check FLGC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
KMDA vs SBFMW Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while SBFMW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas SBFMW's P/E ratio is N/A. In terms of profitability, KMDA's ROE is +0.09%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, KMDA is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check SBFMW's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
KMDA vs GELS Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while GELS trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas GELS's P/E ratio is -0.96. In terms of profitability, KMDA's ROE is +0.09%, compared to GELS's ROE of -0.36%. Regarding short-term risk, KMDA is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check GELS's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
KMDA vs PLXP Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas PLXP's P/E ratio is -0.22. In terms of profitability, KMDA's ROE is +0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, KMDA is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for KMDA.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
KMDA vs ATNX Comparison November 2026
Kamada Ltd. (NASDAQ: KMDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KMDA stands at 469.1M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, KMDA is priced at $8.13 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KMDA currently has a P/E ratio of 21.39, whereas ATNX's P/E ratio is -0.02. In terms of profitability, KMDA's ROE is +0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, KMDA is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for KMDA.Check ATNX's competition here